Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries ProMIS Neurosciences to Present in Upcoming Investor Conferences in April By: ProMIS Neurosciences Inc. via GlobeNewswire April 04, 2024 at 07:00 AM EDT CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 04, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that company management will participate in three upcoming investor conferences: LD Micro Invitational XIV (New York, New York) Neil Warma, Chief Executive Officer, will present a corporate overview on Tuesday, April 9, 2024, at 2:00 p.m. ET. 23rd Annual Needham Virtual Healthcare Conference Neil Warma, Chief Executive Officer, will present a corporate overview on Thursday, April 11, 2024 at 2:15 p.m. ET. Bloom Burton & Co. Healthcare Investor Conference (Toronto, Canada) Neil Warma, Chief Executive Officer, will present a corporate overview on Wednesday, April 17, 2024 at 10:30 a.m. ET. A live webcast of the presentations may be accessed by visiting the Events page of the Company’s website at www.promisneurosciences.com, and will be available for at least 30 days following the event. About ProMIS Neurosciences Inc. ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company’s proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. ProMIS has offices in Toronto, Ontario and Cambridge, Massachusetts. For further information: Visit us at www.promisneurosciences.com Please submit media inquiries to info@promisneurosciences.com. For Investor Relations: Stern Investor RelationsAnne Marie Fields, Managing Directorannemarie.fields@sternir.comTel. 212-362-1200 Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April By: ProMIS Neurosciences Inc. via GlobeNewswire April 04, 2024 at 07:00 AM EDT CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 04, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that company management will participate in three upcoming investor conferences: LD Micro Invitational XIV (New York, New York) Neil Warma, Chief Executive Officer, will present a corporate overview on Tuesday, April 9, 2024, at 2:00 p.m. ET. 23rd Annual Needham Virtual Healthcare Conference Neil Warma, Chief Executive Officer, will present a corporate overview on Thursday, April 11, 2024 at 2:15 p.m. ET. Bloom Burton & Co. Healthcare Investor Conference (Toronto, Canada) Neil Warma, Chief Executive Officer, will present a corporate overview on Wednesday, April 17, 2024 at 10:30 a.m. ET. A live webcast of the presentations may be accessed by visiting the Events page of the Company’s website at www.promisneurosciences.com, and will be available for at least 30 days following the event. About ProMIS Neurosciences Inc. ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company’s proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. ProMIS has offices in Toronto, Ontario and Cambridge, Massachusetts. For further information: Visit us at www.promisneurosciences.com Please submit media inquiries to info@promisneurosciences.com. For Investor Relations: Stern Investor RelationsAnne Marie Fields, Managing Directorannemarie.fields@sternir.comTel. 212-362-1200
CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 04, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that company management will participate in three upcoming investor conferences: LD Micro Invitational XIV (New York, New York) Neil Warma, Chief Executive Officer, will present a corporate overview on Tuesday, April 9, 2024, at 2:00 p.m. ET. 23rd Annual Needham Virtual Healthcare Conference Neil Warma, Chief Executive Officer, will present a corporate overview on Thursday, April 11, 2024 at 2:15 p.m. ET. Bloom Burton & Co. Healthcare Investor Conference (Toronto, Canada) Neil Warma, Chief Executive Officer, will present a corporate overview on Wednesday, April 17, 2024 at 10:30 a.m. ET. A live webcast of the presentations may be accessed by visiting the Events page of the Company’s website at www.promisneurosciences.com, and will be available for at least 30 days following the event. About ProMIS Neurosciences Inc. ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company’s proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. ProMIS has offices in Toronto, Ontario and Cambridge, Massachusetts. For further information: Visit us at www.promisneurosciences.com Please submit media inquiries to info@promisneurosciences.com. For Investor Relations: Stern Investor RelationsAnne Marie Fields, Managing Directorannemarie.fields@sternir.comTel. 212-362-1200